Novo Nordisk initiated a share repurchase program starting February 2026, aiming to buy back up to DKK 15 billion of B shares within 12 months. As of July 17, 2026, the company has repurchased approximately 24.96 million B shares at an average price of DKK 274.58 per share, totaling around DKK 6.85 billion. This buyback reduces the number of shares in circulation and can enhance shareholder value. Novo Nordisk plans to continue repurchasing shares under this program until the limit is reached or the 12-month period ends in February 2027.
Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing the company of misleading advertising for its GLP-1 drugs Zepbound and Mounjaro. Novo claims Lilly's ads use outdated data and unfairly compare Lilly's highest drug doses to lower d...
Novo Nordisk has filed a lawsuit against Eli Lilly, accusing the company of running misleading ads that inaccurately claim superior efficacy of Lilly's obesity and diabetes drugs compared to Novo's. The lawsuit targets ads that use outdated clinical ...
Novo Nordisk's shares have risen about 27% due to strong commercial growth of oral Wegovy, which holds 89% of new U.S. prescriptions compared to Eli Lilly's 11%. Over 80% of these prescriptions are from new GLP-1 patients, expanding the market rather...
Citi has increased its price target for Novo Nordisk to DKK330 ahead of the company's Q2 results, citing strong sales from the Wegovy pill launch. The broker raised its 2026 sales and operating income estimates by 4-5%, and earnings per share forecas...
Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...
